ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2018
MADRID, SPAIN and CAMBRIDGE MA.
• NET PROFIT OF $ 0.65 M (+$0.02 per share).
Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first half of 2018 and provided an update on the Company's recent developments.
R&D investments of € 3.7 million during the first half of 2018 have permitted Oryzon to significantly advance its clinical portfolio. The most significant one has been the CTA approval from the Medicines Regulatory Agencies in Spain, France and the United Kingdom to start ETHERAL, a Phase IIa clinical trial in patients with mild and moderate Alzheimer's disease treated with VAFIDEMSTAT (ORY-2001). The recruitment of the first patients in the period has been also announced.